As filed with the Securities and Exchange Commission on March 3, 2015
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
MACROGENICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
06-1591613
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
| |
|
|
|
9640 Medical Center Drive, Rockville, MD
|
|
20850
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
2013 Equity Incentive Plan
(Full title of the plan)
Scott Koenig, M.D., Ph.D.
President and Chief Executive Officer
9640 Medical Center Drive
Rockville, MD 20850
(Name and address of agent for service)
(301) 251-5172
(Telephone number, including area code, of agent for service)
Copies to:
|
Atul Saran
Senior Vice President and General Counsel
9640 Medical Center Drive
Rockville, MD 20850
(301) 251-5172
|
Richard E. Baltz
Arnold & Porter LLP
555 Twelfth Street NW
Washington, DC 20004
(202) 942-5000
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer ¨
|
Accelerated filer x
|
|
Non-accelerated filer ¨ (Do not check if a smaller reporting company)
|
Smaller Reporting Company ¨
|
CALCULATION OF REGISTRATION FEE
|
Title of securities
to be registered
|
|
Amount
to be
registered(1)
|
|
Proposed
maximum
offering price
per share
|
|
Proposed
maximum
aggregate
offering price
|
|
Amount of
registration fee
|
|
Common Stock, $0.01 par value per share
|
|
2,126,930 shares
|
|
$34.91(2)
|
|
$74,251,126.30(2)
|
|
$8,628
|
(1) In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are calculated on the basis of $34.91, the average of the high and low price of the registrant's Common Stock as reported on the NASDAQ Global Market on February 27, 2015.
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 2,126,930 shares of common stock of MacroGenics, Inc. (the "Company") issuable pursuant to the Company's 2013 Equity Incentive Plan. Accordingly, the contents of the Company's registration statement on Form S-8 filed with the SEC on November 12, 2013 (Registration No. 333-192277) are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Certain Documents by Reference.
The SEC allows us to "incorporate by reference" information into this Registration Statement, which means that we can disclose important information to you by referring to those documents. We hereby "incorporate by reference" the documents listed below, which means that we are disclosing important information to you by referring you to those documents. The information that we file later with the SEC will automatically update and in some cases supersede this information. Specifically, we incorporate by reference the following documents or information filed with the SEC (other than, in each case, documents or information deemed to have been furnished and not filed in accordance with SEC rules):
|
a)
|
The Company's latest Annual Report filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or latest prospectus filed pursuant to Rule 424(b) under the Securities Act that contains audited financial statements for the latest fiscal year for which such statements have been filed;
|
|
b)
|
All other reports filed by the Company pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Company's latest annual report or prospectus referred to in (a) above;
|
|
c)
|
The description of the Company's common stock contained in its Registration Statement on Form 8-A filed on October 7, 2013, including any amendments or reports filed for the purpose of updating such description; and
|
|
d)
|
Future filings the Company makes with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and before the filing of any post-effective amendment to this Registration Statement which indicates that all securities offered under this Registration Statement have been sold or which deregisters all such securities then remaining unsold.
|
Any statement, including financial statements, contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or therein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement
The exhibits to this Registration Statement are described in the Exhibit Index below.
Pursuant to the requirements of the Securities Act of 1933, as amended (the "Securities Act"), the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland, on March 3, 2015.
DATE: March 3, 2015 By: /s/ Scott Koenig
Name: Scott Koenig, M.D., Ph.D.
Title: President and Chief Executive Officer
We, the undersigned directors and officers of MacroGenics, Inc., a Delaware corporation, do hereby constitute and appoint Scott Koenig, Chief Executive Officer, and James Karrels, Chief Financial Officer, and each and either of them, our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, to do any and all acts and things in our names and on our behalf in our capacities as directors and officers and to execute any and all instruments for us and in our name in the capacities indicated below, which said attorneys and agents may deem necessary or advisable to enable said corporation to comply with the Securities Act and any rules, regulations and requirements of the SEC, in connection with this registration statement, or any registration statement for this offering under the Securities Act, including specifically, but without limitation, any and all amendments (including post-effective amendments) hereto; and we hereby ratify and confirm all that said attorneys and agents, or either of them, shall do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons on March 3, 2015.
|
SIGNATURE:
|
|
TITLE:
|
| |
|
|
|
/s/ Scott Koenig
|
|
President and CEO and Director
|
|
Scott Koenig, M.D., Ph.D.
|
|
(Principal Executive Officer)
|
| |
|
|
|
/s/ James Karrels
|
|
Senior Vice President, Chief Financial Officer and Secretary (Principal Financial Officer)
|
|
James Karrels
|
|
| |
|
|
|
/s/ Lynn Cilinski
|
|
Vice President, Controller and Treasurer
(Principal Accounting Officer)
|
|
Lynn Cilinski
|
| |
|
|
|
/s/ Paulo Costa
|
|
Director
|
|
Paulo Costa
|
|
|
| |
|
|
|
/s/ Matthew Fust
|
|
Director
|
|
Matthew Fust
|
|
|
| |
|
|
|
/s/ Kenneth Galbraith
|
|
Director
|
|
Kenneth Galbraith
|
|
|
| |
|
|
|
/s/ Edward Hurwitz
|
|
Director
|
|
Edward Hurwitz
|
|
|
| |
|
|
|
/s/ David Stump
|
|
Director
|
|
David Stump, M.D.
|
|
|
INDEX TO EXHIBITS
5.1 Opinion of Arnold & Porter LLP
23.1 Consent of Arnold & Porter LLP (included in Exhibit 5.1)
23.2 Consent of Ernst & Young LLP
24.1 Power of Attorney (included on signature page)